All In Biotech

Drug Trial Radar · NCT03131648

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy

Last checked: Nov 20, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 802 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

802

Actual

Start

May 30, 2017

Primary completion

Aug 7, 2018

Study completion Oct 10, 2019

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Apr 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD). Secondary objectives: To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health related quality of life compared with placebo. Maintenance objective: To evaluate maintenance of effect with continued tralokinumab dosing up to 52 weeks compared to placebo for subjects achieving clinical response at Week 16.

Conditions

  • Atopic Dermatitis

Interventions

  • TralokinumabDrug

    Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

  • PlaceboDrug

    Placebo contains the same excipients, in the same concentration only lacking tralokinumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16Time frame: At Week 16
  2. Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 16Time frame: At Week 16

Locations

123 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Research Center of Alabama

    Birmingham, Alabama

  • Tien Q. Nguyen, MD, Inc.

    Fountain Valley, California

  • Dermatology Research Associates

    Los Angeles, California

  • Quest Dermatology Research

    Northridge, California

  • Dermatology Specialists, Inc.

    Oceanside, California

  • Center for Dermatology and Laser Surgery

    Sacramento, California

  • University Clinical Trials, Inc.

    San Diego, California

  • The GWU Medical Faculty Associates

    Washington D.C., District of Columbia

  • Skin Care Research, Inc.

    Boca Raton, Florida

  • Park Avenue Dermatology

    Orange Park, Florida

  • Forward Clinical Trials

    Tampa, Florida

  • Research Institute of the Southeast, LLC

    West Palm Beach, Florida

  • ACRC Dermatology

    West Palm Beach, Florida

  • Georgia Pollens Clinical Research Centers, Inc.

    Albany, Georgia

  • Allergy Center at Brookstone Research

    Columbus, Georgia

  • Dermatologic Surgery Specialists

    Macon, Georgia

  • Meridian Clinical Research

    Savannah, Georgia

  • Altman Dermatology Associates

    Arlington Heights, Illinois

  • PMG Research of Christie Clinic

    Chicago, Illinois

  • Deaconess Clinic

    Evansville, Indiana

  • Skin Sciences, PLLC

    Louisville, Kentucky

  • Clinical Trials of SWLA, LLC

    Lake Charles, Louisiana

  • DermAssociates, PC

    Rockville, Maryland

  • Clarkston Skin Research

    Clarkston, Michigan

  • Derm Center

    Troy, Michigan

  • MediSearch LLC

    Saint Joseph, Missouri

  • JDR Dermatology Research

    Las Vegas, Nevada

  • University at Buffalo Department of Dermatology

    Buffalo, New York

  • Weil Cornell Medicine

    New York, New York

  • Juva Skin & Laser Center

    New York, New York

  • Deramatology Consulting Services, PLLC

    High Point, North Carolina

  • Dermatologists of Greater Columbus

    Bexley, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Oregon Medical Research Center

    Portland, Oregon

  • Oregon Health & Sciences University

    Portland, Oregon

  • UPMC Department of Dermatology

    Pittsburgh, Pennsylvania

  • Austin Dermatology Associates

    Austin, Texas

  • Tekton Research

    Austin, Texas

  • Dermtology Treatment and Research Center

    Dallas, Texas

  • Houston Skin Associates

    Houston, Texas

Showing 40 of 123 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.